PMID- 30574151
OWN - NLM
STAT- MEDLINE
DCOM- 20191025
LR  - 20200309
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - Intestinal Dendritic Cells in Health and Gut Inflammation.
PG  - 2883
LID - 10.3389/fimmu.2018.02883 [doi]
LID - 2883
AB  - Dendritic cells (DCs) mediate tolerance to food antigens, limit reactivity to the 
      gut microbiota and are required for optimal response to intestinal pathogens. 
      Intestinal DCs are heterogeneous but collectively generate both regulatory and 
      effector T cell responses. The balance of outcomes is determined by the activity 
      of functionally distinct DC subsets and their modulation by environmental cues. 
      DCs constantly sample luminal content to monitor for pathogens; the significance 
      of the various pathways by which this occurs is incompletely understood. 
      Intestinal DC have distinctive properties shaped by local host, dietary and 
      microbial signals. These properties include the ability to produce all-trans 
      retinoic acid (RA) and imprint gut tropism on T cells they activate. In the 
      steady-state, subsets of intestinal DC are potent generators of inducible Treg, 
      aided by their ability to activate TGFbeta and produce RA. However, responses 
      induced by steady-state intestinal DCs are not exclusively regulatory in nature; 
      effector T cells with specificity for commensal bacterial can be found in the 
      healthy mucosa and these can be locally controlled to prevent inflammation. The 
      ability of intestinal DCs to enhance effector responses in infection or sustain 
      inflammation in disease is likely to involve both modulation of the local DC 
      population and recruitment of additional populations. Immune pathways in the 
      pathogenesis of inflammatory bowel disease can be mapped to DCs and in inflamed 
      intestinal tissue, DCs show increased expression of microbial recognition 
      machinery, activation, and production of key immunological mediators. Intestinal 
      DCs may be targeted for disease therapy or to improve vaccine responses.
FAU - Stagg, Andrew J
AU  - Stagg AJ
AD  - Centre for Immunobiology, Blizard Institute, Barts and The London School of 
      Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20181206
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Allergens)
RN  - 0 (Immunologic Factors)
RN  - 0 (Transforming Growth Factor beta)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Allergens/immunology
MH  - Animals
MH  - Cell Communication/*immunology
MH  - Colitis/*immunology/microbiology
MH  - Dendritic Cells/*immunology/metabolism
MH  - Disease Models, Animal
MH  - Food Hypersensitivity/immunology
MH  - Gastrointestinal Microbiome/immunology
MH  - Humans
MH  - *Immunity, Mucosal
MH  - Immunologic Factors/immunology/metabolism
MH  - Intestinal Mucosa/cytology/*immunology/metabolism/microbiology
MH  - Intraepithelial Lymphocytes/immunology/metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology/metabolism
MH  - T-Lymphocytes, Regulatory/immunology/metabolism
MH  - Transforming Growth Factor beta/immunology/metabolism
MH  - Tretinoin/immunology/metabolism
PMC - PMC6291504
OTO - NOTNLM
OT  - Dendritic cells
OT  - antigen sampling
OT  - inflammatory bowel disease
OT  - intestinal inflammation
OT  - lymphocyte homing
EDAT- 2018/12/24 06:00
MHDA- 2019/10/28 06:00
PMCR- 2018/01/01
CRDT- 2018/12/22 06:00
PHST- 2018/07/13 00:00 [received]
PHST- 2018/11/23 00:00 [accepted]
PHST- 2018/12/22 06:00 [entrez]
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2019/10/28 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.02883 [doi]
PST - epublish
SO  - Front Immunol. 2018 Dec 6;9:2883. doi: 10.3389/fimmu.2018.02883. eCollection 
      2018.